Kayfanda

Odevixibat, the active ingredient in Kayfanda, is an IBAT inhibitor presented as an oral formulation for oral use. It is used to treat cholestatic liver disorders such as progressive familial intrahepatic cholestasis, Alagille syndrome, and pruritus associated with cholestatic disease in pediatric and adult patients. GNH USA supplies Kayfanda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Kayfanda acts on the bile acid transport pathway to manage cholestatic liver conditions. - Progressive familial intrahepatic cholestasis (PFIC): reduces bile acid accumulation and improves liver function. - Alagille syndrome: alleviates cholestasis and associated itching. - Pruritus associated with cholestatic liver disease: decreases bile‑acid‑induced itching and improves quality of life.

Adverse reactions have been observed in clinical use of Odevixibat.

Common Side Effects: - Diarrhea: frequent loose stools. - Abdominal pain: mild to moderate discomfort. - Nausea: occasional feeling of sickness. - Fatigue: reduced energy levels. - Elevated liver enzymes: mild increases in ALT/AST. - Vitamin deficiencies: reduced absorption of fat‑soluble vitamins.

Serious or Rare Side Effects: - Severe dehydration: secondary to persistent diarrhea. - Acute liver injury: marked elevation of liver enzymes. - Severe abdominal pain requiring medical attention. - Allergic reactions: rash, urticaria, or anaphylaxis. - Electrolyte imbalance: especially low potassium due to gastrointestinal loss.

When prescribing Kayfanda, clinicians should consider several safety measures. - Liver function monitoring: assess ALT, AST, bilirubin regularly. - Hydration status: ensure adequate fluid intake to prevent dehydration. - Vitamin supplementation: monitor and replace fat‑soluble vitamins as needed. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Renal function: evaluate kidney function in patients with pre‑existing impairment. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Odevixibat may alter the absorption of concomitant medications.

Major Interactions (Avoid): - Fat‑soluble vitamin supplements: may have reduced absorption, requiring dose adjustment. - Oral contraceptives: decreased efficacy due to altered bile‑acid mediated absorption. - Lipid‑soluble drugs (e.g., cyclosporine): potential reduction in systemic exposure.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may affect gastrointestinal pH and drug dissolution. - Antibiotics with enterohepatic recycling (e.g., rifampin): possible decreased effectiveness. - Statins: monitor lipid levels as absorption may be modestly reduced.